Science

Human antibody-producing transgenic H2L2TM mice have been used to generate monoclonal antibodies to therapeutic targets. Transgenic animals producing human antibodies are by far the most successful approach to obtaining “fully human” therapeutic antibodies. This is largely due to the ability to move transgenic animalderived human antibodies from lead selection directly to clinical development without undergoing lead optimization steps common with humanization of murine Abs or affinity maturation of Abs from phage or other synthetic libraries.

Summary

Antibody Solutions has successfully used Harbour Antibodies’ H2L2™ mouse in our Hybridoma Library™ platform to generate 272 monoclonal human antibodies to an immune checkpoint therapeutic target, “HBM-1”. The panel of HBM-1 antibodies display a diverse range of target binding affinity by flow cytometry, cross-reactivity to cynomologus HBM-1, and blocking of HBM-1 binding to its ligand.

Download this poster

We invite you to download our poster that details this research study, including our antibody discovery strategy as well as the Spike protein reagents, screening assay formats, and more that we utilized.

Authors

Joshua Lowitz, John S. Kenney, Glen Lin, Rick Chang, Jennifer Somera, Leonel Santibanez-Vargas, Julia Teplyuk, Catherine Vo, Emmeline Truong, Billy Nguyen, Zhiping Yao, Yiping Rong, and Jiuqiao Zhao, Antibody Solutions, Sunnyvale, CA, USA & Harbour BioMed, Newton, MA, USA